Merck has partnered with Xi'an Janssen to launch an innovative adult type 2 diabetes treatment with a new drug, Acoad®

China has 114 million people with diabetes, the highest number in the world, according to the 2017 Diabetes Map released by the International Diabetes FederationAccording to the 2017 edition of China's Guidelines for the Prevention and Control of Type 2 Diabetes (2017), the prevalence of type 2 diabetes in adults in China is 10.4%studies also show that the number of people with diabetes is increasing year by year, and that many people diagnosed with diabetes at a young age are still struggling to control their blood sugarAbout half of adult diabetics do not reach the recommended blood sugar control levels, increasing the risk of potentially life-threatening complications such as heart disease, stroke, kidney failure and diabetic retinopathythe latest news, Merck and Xi'an YangsenPharmaceutical(LimitedCompany(in Beijing signed a cooperation agreement to launch innovative adult type 2 diabetes treatment newdrug(Ikea ® (CagleNet)based on the cooperation agreement signed between the two parties, the two companies will work closely on the follow-up development, distribution, promotion, access, marketing and sales of the Ikea ® ,which Merck has the right toof theproducts (exclusive promotion rights in the Chinese market)a new drug for Ake's ®
Ake's ® (Caglenet) as one of the new drugs for sodium-glucose co-transit protein (SGLT-2) inhibitors, approved in China in September 2017When blood glucose control is poor with metformin or metformin and sulfonym alone, Acoa® (Cagle net) can be combined with metformin or metformin and sulfonya to improve blood sugar control in adult semen type 2 diabetes patients Akean ® (Cagle net) with the new non-insulin dependence mechanism, by highly selective inhibition of SGLT-2, thereby reducing the reabsorption of the kidneys to the filtered glucose, reducing renal sugar threshold, increased urine sugar excretion, thereby reducing blood sugar in patients with type 2 diabetes In addition to a clear sugar reduction effect, it can also reduce additional benefits such as weight loss, delaying proteinuria and lower blood pressure the launch of the Ikea ® (Cagle Net) is another innovative diabetes treatment by Merck, following the ® of Gwasted (metformin hydrochloride) and other diabetes products The launch of The ® of Ake (Cagle Net) further enriches Merck's product line of diabetes treatment drugs, providing more and more innovative treatment options for the vast majority of diabetics in China and improving the quality of life